Review
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Mar 18, 2022; 12(3): 27-41
Published online Mar 18, 2022. doi: 10.5500/wjt.v12.i3.27
Innovative immunosuppression in kidney transplantation: A challenge for unmet needs
Maurizio Salvadori, Aris Tsalouchos
Maurizio Salvadori, Department of Renal Transplantation, Careggi University Hospital, Florence 50139, Italy
Aris Tsalouchos, Division of Nephrology, Santa Maria Annunziata Hospital, Florence 50012, Italy
Author contributions: Salvadori M and Tsalouchos A contributed equally to the manuscript; Salvadori M designed the study, performed the last revision and provided answers to the reviewers; Tsalouchos A collected the data from literature; Salvadori M and Tsalouchos A analyzed the collected data and wrote the manuscript.
Conflict-of-interest statement: Salvadori M and Tsalouchos A do not have any conflict of interest in relation to the manuscript, as in the attached form.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maurizio Salvadori, MD, Professor, Department of Renal Transplantation, Careggi University Hospital, Largo Palagi 1, Florence 50139, Italy. maurizio.salvadori1@gmail.com
Received: October 22, 2021
Peer-review started: October 22, 2021
First decision: January 22, 2022
Revised: January 27, 2022
Accepted: March 6, 2022
Article in press: March 6, 2022
Published online: March 18, 2022
Processing time: 146 Days and 16.8 Hours
Core Tip

Core Tip: Finding new innovative drugs for kidney transplantation is not easy but looking for unmet needs it is possible to find new interesting drugs and opportunities to use in kidney transplantation. Many of these drugs are just at the beginning of their process toward the approval and should be careful checked until the finish of their path. Principal unmet needs are treatment and prevention of delayed graft function, improve the long-term outcomes, desensitization and treatment of acute antibody-mediated rejection. Finding new drugs in these fields results extremely important to face new kind of transplantation as transplant from non-heart beating donor and transplant in ABO incompatibles pairs.